Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Emma Zattarin"'
Autor:
Laura Pala, Eleonora Pagan, Isabella Sala, Chiara Oriecuia, Matteo Oliari, Tommaso De Pas, Claudia Specchia, Emilia Cocorocchio, Emma Zattarin, Giovanna Rossi, Chiara Catania, Giovanni Luca Ceresoli, Daniele Laszlo, Jacopo Canzian, Elena Valenzi, Giuseppe Viale, Richard D. Gelber, Alberto Mantovani, Vincenzo Bagnardi, Fabio Conforti
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102681- (2024)
Summary: Background: The outcome of patients with metastatic tumors who discontinued immune checkpoint inhibitors (ICIs) not for progressive disease (PD) has been poorly explored. We performed a meta-analysis of all studies reporting the clinical out
Externí odkaz:
https://doaj.org/article/b1b86a103a1c4b248e0c5fec79d7f359
Autor:
Laura Pala, Tommaso De Pas, Eleonora Pagan, Isabella Sala, Chiara Catania, Emma Zattarin, Paolo Arnone, Massimo M. Grassi, Marco Colleoni, Antonio C. Wolff, Javier Cortes, Martine Piccart, Richard D. Gelber, Giuseppe Viale, Vincenzo Bagnardi, Fabio Conforti
Publikováno v:
Breast, Vol 69, Iss , Pp 258-264 (2023)
Background: Controversy exists regarding the optimal duration of the extended adjuvant endocrine treatment (ET) in patients with early-stage breast-cancer (eBC).We performed a systematic review and trial-level meta-analysis of all randomized clinical
Externí odkaz:
https://doaj.org/article/8e6fc51cd6204dc49c4a3e7115ddcbda
Autor:
Laura Pala, Isabella Sala, Eleonora Pagan, Tommaso De Pas, Emma Zattarin, Chiara Catania, Emilia Cocorocchio, Giovanna Rossi, Daniele Laszlo, Giovanni Ceresoli, Jacopo Canzian, Elena Valenzi, Vincenzo Bagnardi, Fabio Conforti
Publikováno v:
Breast, Vol 73, Iss , Pp 103672- (2024)
Introduction: To provide evidence explaining the poor association between pCR and patients’ long-term outcome at trial-level in neoadjuvant RCTs for breast cancer (BC), we performed a systematic-review and meta-analysis of all RCTs testing neoadjuv
Externí odkaz:
https://doaj.org/article/8b42a9ebb27043a0b4f19d11a28e6528
Autor:
Emma Zattarin, Luigi Mariani, Alice Menichetti, Rita Leporati, Leonardo Provenzano, Francesca Ligorio, Giovanni Fucà, Riccardo Lobefaro, Luca Lalli, Andrea Vingiani, Federico Nichetti, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Chiara Corti, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Daniele Presti, Caterina Sposetti, Carlo Alberto Giorgi, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Daniele Generali, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2− aBC). Objectives: While CDK4/6i
Externí odkaz:
https://doaj.org/article/997ec44c91b244349cd2462f6a583683
Autor:
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-5 (2023)
Abstract Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 pat
Externí odkaz:
https://doaj.org/article/1b8f8d9603654e7590deb24e3d8b863d
Autor:
Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3494-3499 (2023)
Small-cell lung cancer (SCLC) transformation from EGFR mutant adenocarcinoma is a rare entity that is considered to be a new phenotype of SCLC. While transformation from adenocarcinoma (ADC) with EGFR exon 19 deletions and exon 21 L858R point mutatio
Externí odkaz:
https://doaj.org/article/4960412eb78643b0975752392593a027
Autor:
Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri, Giovanni Fucà
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Advanced triple-negative breast cancer (aTNBC) has a poor prognosis; thus, there is a need to identify novel biomarkers to guide future research and improve clinical outcomes. Objectives: We tested the prognostic ability of an emerging, c
Externí odkaz:
https://doaj.org/article/d60a1af664724f99bf39ed7dd7ca1413
Autor:
Federico Nichetti, Francesca Ligorio, Giulia Montelatici, Luca Porcu, Emma Zattarin, Leonardo Provenzano, Andrea Franza, Luca Lalli, Filippo de Braud, Marco Platania
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Hospitalized cancer patients are at increased risk for Thromboembolic Events (TEs). As untailored thromboprophylaxis is associated with hemorrhagic complications, the definition of a risk-assessment model (RAM) in this population is needed.
Externí odkaz:
https://doaj.org/article/9995703f54ba4beaa82758302c0bb1ca
Autor:
Emma Zattarin, Federico Nichetti, Francesca Ligorio, Laura Mazzeo, Riccardo Lobefaro, Giovanni Fucà, Giorgia Peverelli, Andrea Vingiani, Giulia V. Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Extramammary Paget disease (EMPD) is a rare form of cutaneous, intraepithelial adenocarcinoma, which typically presents itself as an erythematous plaque originating from apocrine-gland rich regions, such as the vulva, the perianal region, the scrotum
Externí odkaz:
https://doaj.org/article/02ed4f0921e249db898877b9b34d54a9
Autor:
Francesca Ligorio, Luca Zambelli, Giovanni Fucà, Riccardo Lobefaro, Marzia Santamaria, Emma Zattarin, Filippo de Braud, Claudio Vernieri
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Human Epidermal growth factor Receptor 2 (HER2) overexpression or HER2 gene amplification defines a subset of breast cancers (BCs) characterized by higher biological and clinical aggressiveness. The introduction of anti-HER2 drugs has remarkably impr
Externí odkaz:
https://doaj.org/article/9e73ed9583ae4cee885a74db768a4b79